These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21792083)

  • 1. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
    Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
    Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
    Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
    Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
    Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
    Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
    Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
    Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
    Yamaguchi Y; Katata Y; Okawaki M; Sawaki A; Yamamura M
    Anticancer Res; 2016 May; 36(5):2307-13. PubMed ID: 27127137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
    BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer.
    Koido S; Taguchi J; Shimabuku M; Kan S; Bito T; Misawa T; Ito Z; Uchiyama K; Saruta M; Tsukinaga S; Suka M; Yanagisawa H; Sato N; Ohkusa T; Shimodaira S; Sugiyama H
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
    Murakami Y; Uemura K; Sudo T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Oct; 108(10):1661-9. PubMed ID: 21971141
    [No Abstract]   [Full Text] [Related]  

  • 15. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.
    Bauer C; Dauer M; Saraj S; Schnurr M; Bauernfeind F; Sterzik A; Junkmann J; Jakl V; Kiefl R; Oduncu F; Emmerich B; Mayr D; Mussack T; Bruns C; Rüttinger D; Conrad C; Jauch KW; Endres S; Eigler A
    Cancer Immunol Immunother; 2011 Aug; 60(8):1097-107. PubMed ID: 21547597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
    Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
    Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
    Kasuga A; Okano N; Naruge D; Kitamura H; Takasu A; Nagashima F; Furuse J
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):457-64. PubMed ID: 25547407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
    Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
    Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
    Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
    Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.